Magenta Therapeutics (NASDAQ:MGTA): Q1 GAAP EPS of -$0.51 beats by $0.12.
Cash, equivalents and marketable securities of $130.41M (-10.5% Q/Q)
https://seekingalpha.com/news/3571159-magenta-therapeutics-eps-beats-0_12Thursday, May 7, 2020
ANI Pharmaceuticals EPS beats by $0.15, misses on revenue
ANI Pharmaceuticals (NASDAQ:ANIP): Q1 Non-GAAP EPS of $1.04 beats by $0.15; GAAP EPS of -$0.59 misses by $0.58.
Revenue of $49.77M (-5.9% Y/Y) misses by $0.46M.
https://seekingalpha.com/news/3571193-ani-pharmaceuticals-eps-beats-0_15-misses-on-revenuePuma Bio’s Nerlynx OK’d in China
Puma Biotechnology (NASDAQ:PBYI) announces that
China’s National Medical Products Administration has approved Nerlynx
(neratinib) for the extended adjuvant treatment of adult patients with
early-stage human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, following adjuvant therapy with trastuzumab (branded as
Herceptin by Roche).
Licensee CANbridge Pharmaceuticals will commercialize.
Shares up 5% premarket on light volume.
https://seekingalpha.com/news/3571252-puma-bios-nerlynx-okd-in-chinaNovo Nordisk Q1 top-line up 16%; guidance affirmed
Novo Nordisk (NVO) Q1 results (DKK):
Revenues: 33,875M (+15.6%); Diabetes and Obesity care: 28,591M (+15.2%); Biopharm: 5,284M (+18.1%).
Long-acting insulin: 5,158M (-2%); Fast-acting
insulin: 5,114M (+3%); Premix insulin: 2,955M (+7%); Human insulin:
2,687M (+11%); Total GLP-1: 9,975M (+40%); Obesity care (Saxenda):
1,577M (+30%); Haemophilia: 2,810M (+11%); Growth disorders
(Norditropin): 2,030M (+31%).
Key product sales: NovoRapid: 4,724M (-0.5%);
Victoza: 4,991M (-13%); Ozempic: 4,755M; Tresiba: 2,460M (+15%);
Levemir: 2,036M (-22%); NovoMix: 2,618 (+3%); NovoSeven: 2,181M (+8%).
Net Income: 11,897M (+13.9%); EPS: 5.05 (+15.8%).
CF Ops: 10,012M (+1.2%).
2020 Guidance: Sales growth (at
CER): 3% – 6% (unch); Operating profit (at CER): 1% – 5% (unch); CAPEX:
Around DKK6.5B (unch); Free cash flow: 36B – 41B (unch).
Shares are up 2% premarket.
Previously: Novo Nordisk reports Q1 results (May 7)
https://seekingalpha.com/news/3571256-novo-nordisk-q1-top-line-up-16-guidance-affirmedSmileDirectClub to support teledentistry via sale of at-home kits to providers
Aimed at supporting the increased use of telehealth during the pandemic, SmileDirectClub (SDC +4.0%)
will now sell its at-home impression kits to dentists and orthodontists
enabling them to remotely provide oral care to patients.
The company will ship the kits directly to patients pursuant to the receipt of prescriptions and will have prepaid return labels to their providers’ offices.
https://seekingalpha.com/news/3571258-smiledirectclub-to-support-teledentistry-via-sale-of-home-kits-to-providersRite Aid expands COVID-19 testing to include asymptomatics
Rite Aid (RAD +5.4%) announces the
addition of 46 no-charge sample collection sites, most via
drive-through windows, increasing the total number of sites to 71 (up
from 25 sites in late April).
It has also expanded the COVID-19 testing criteria for adults (at least 18 years old) to include asymptomatic people.
https://seekingalpha.com/news/3571273-rite-aid-expands-covidminus-19-testing-to-include-asymptomaticsLannett down after FQ3 earnings miss, guidance cut
Net sales: $144.4M (-16.4%).
Net loss: ($16.6M) (-256.7%); non-GAAP net income: $11.7M (-56.0%); loss/share: ($0.43) (-259.3%); non-GAAP EPS: $0.27 (-60.3%).
Non-GAAP EBITDA: $35.9M.
2020 guidance: Net sales: $535M – 545M from $530M – 550M; non-GAAP EBITDA: $137M – 147M from $145M – 160M.
https://seekingalpha.com/news/3571283-lannett-down-after-fq3-earnings-miss-guidance-cut
Subscribe to:
Posts (Atom)